Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from diverse populations.

Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic disease targets.

Novo Nordisk will provide Variant with an upfront payment and additional near-term R&D funding that could reach up to $50m.

The deal expands a deal to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using human data and AI.

Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of America addresses the company’s earnings and more.

An experimental Novo Nordisk anti-obesity treatment helped patients lose less than a quarter of their bodyweight in a new study, missing the company's expectations and sending its shares tumbling.

Our suite of first-mover leveraged & thematic ETFs empowers investors to express targeted views on disruptive innovations, including artificial intelligence, machine learning, and quantum ...

The expanded collaboration will continue to leverage the capabilities of Valo’s Opal Computational Platform™, as well as key joint capabilities in human data and genetics with Novo Nordisk’s expertise ...

Novo Nordisk A/S and Valo Health, Inc. today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, ty ...